glp-1 compounding crackdown news october 2025 National Hispanic Medical Association | The federal government is stepping up to stop counterfeit weight-loss drugs. In 2025, bipartisan lawmakers urged stronger FDA enforcement Non-Traditional Channels: The Compounded GLP-1

Its sale to the public is explicitly illegal in the UK, Australia, and New Zealand

As a theoretical combination risk, the stacked pro-angiogenic activity of TB-500, BPC-157 and GHK-Cu via VEGF applies

Patients should speak to their dermatologist before trying topical glutathione, Malhotra says

Current UK regulatory position includes: Warnings and precautions regarding thyroid C-cell tumours based on animal data, with acknowledgement that human relevance is uncertain Advice regarding pancreatitis risk, with recommendations to discontinue if acute pancreatitis is suspected and not to restart if confirmed No restrictions based on general cancer risk, as human evidence does not support an increased overall malignancy risk Monitoring for gallbladder disease, which has been associated with GLP-1 receptor agonist use The Summary of Product Characteristics (SmPC) for each GLP-1 medicine includes detailed safety information that healthcare professionals should review before prescribing